Press relese November 29th, 2022

SymbioPharm and TargEDys enter an exclusive partnership to launch SymbioLife® Satylia® in Germany

Herborn, November 29th, 2022. – SymbioPharm and TargEDys have signed an exclusive marketing and distribution agreement to launch SymbioLife® Satylia® in Germany. The novel dietary supplement based on the next generation probiotic Hafnia alvei HA4597® will be available from January 2023.

SymbioLife® Satylia® is a precision probiotic with a characterized mechanism of action at molecular level: It increases satiety thanks to the protein ClpB produced by the probiotic strain Hafnia alvei HA4597®. ClpB naturally mimics the human satiety hormone alpha-MSH. The improved feeling of satiety helps with successful weight loss, as confirmed by a clinical study with 230 overweight adults. This natural principle provided by SymbioLife® Satylia® is a new, natural, safe and effective weight management solution and has won multiple awards.

“We are extremely proud and excited about this new collaboration. SymbioPharm is in the top 3 of the German probiotics market and fathered one of the first probiotic pharmaceuticals globally”, Gregory Lambert, CEO of TargEDys says. “With the team’s knowledge of probiotic Enterobacteria, their strong position with doctors, pharmacies, and synergies with probiotics and diagnostics, they are the perfect partner for this premium, highly scientific product.”

“We are very excited to partner with TargEDys and work together on a new era of evidence-based probiotics. With the availability of the patent-protected probiotic Hafnia alvei HA4597®, the knowledge of its biological mechanism of action and the outstanding studies, we can now offer an effective solution for the growing problem areas of obesity and metabolic health” adds Juergen Eck, Co-CEO and CTO of SymbioPharm. “As pioneers in microbiome research and medical probiotics, we are proud to now also help shape the introduction of knowledge-based precision probiotics.“

About TargEDys®

TargEDys® is a commercial-stage French biotech specialized in the development of nutraceutical solutions through microbiome interventions. The company is based on 15 years of research on the microbiota conducted within academic laboratories. TargEDys® develops a product portfolio focusing on overweight, undernutrition, and mental health, all based on the concept of PreciBiomic strains backed by a molecular mechanism of action and in vivo studies.

About SymbioPharm

SymbioPharm GmbH is a pioneer in microbiome research and knowledge-based probiotics - since 1954. Its mission is to preserve health and to heal diseases with probiotic bacteria – making use of the purely biological effect of natural occuring bacteria. Therefore, it researches the human microbiome and develops innovative microbiological therapy approaches. The company holds a state-of-the-art production facility, and with its 120 employees including in-house physicians, medical scientists and microbiological experts, showcases comprehensive expertise from diagnostics – with the Institute for Microecology – to solutions, with the ranges Symbioflor®, SymbioLact®, Symbiofem®, SymbioPet®, and now SymbioLife®.


Download Press release

Here you have the possibility to download our press release:

Download as PDF version

Satylia packshot high resolution

Satylia packshot low resolution

Company logo SymbioPharm

Company logo TargEDys


Angelika Hecht

Phone: +49 (0)2772 981 - 350
Fax: +49 (0)2772 981 - 151

SymbioPharm GmbH
Auf den Lüppen 10
D 35745 Herborn

Search the website: